ClinicalTrials.Veeva

Menu

Immune Response in Lung Cancer (IRLC)

L

Lithuanian University of Health Sciences

Status

Completed

Conditions

Lung Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT01955343
IRLC-1109

Details and patient eligibility

About

This study is designed to evaluate the importance of the immune cells localization (distribution) between malignant tumor islets and surrounding stroma and to investigate the associations between these immune cells as well as cytokines and clinicopathological and prognostic factors of non-small cell lung cancer (NSCLC) patients.

Enrollment

100 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Eastern Cooperative Oncology Group (ECOG) score of 0-1
  • Patients with histologically documented non-small cell lung cancer
  • Control group - patients without non-small cell lung cancer
  • Written (signed) Informed Consent to participate in the study

Exclusion criteria

  • Any other malignancies within 5 years
  • Any unstable systemic disease (including active infections, significant cardiovascular disease)
  • Prior chemotherapy or radiotherapy
  • Autoimmune disease
  • Nursing or pregnant women

Trial design

100 participants in 2 patient groups

Lung cancer
Description:
Newly diagnosed and untreated non small cell lung cancer patients who underwent surgical resection for NSCLC (pathological stage I-III)
Control
Description:
Subjects who will have surgery due to recurrent spontaneous pneumothorax Patients without lung cancer or other malignancies

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems